Trending Now
We have updated our Privacy Policy and Terms of Use for Eurasia Group and its affiliates, including GZERO Media, to clarify the types of data we collect, how we collect it, how we use data and with whom we share data. By using our website you consent to our Terms and Conditions and Privacy Policy, including the transfer of your personal data to the United States from your country of residence, and our use of cookies described in our Cookie Policy.
On Thursday, February 4, Johnson & Johnson requested emergency FDA approval for its single-shot vaccine. In the days since the company first released efficacy and safety data, many of the headlines focused on its lower efficacy rate compared to that of mRNA vaccines from Pfizer and Moderna. But that's the wrong takeaway, says surgeon, public health expert and former member of Biden-Harris Transition COVID-19 Advisory Board, Dr. Atul Gawande. "This is a highly effective vaccine. It stops people from getting sick. If some people have some sniffles and mild effects from the coronavirus, that's okay, this is going to stop the deadly disease. And that is the ultimate goal of the vaccine."
Gawande's conversation with Ian Bremmer is part of the latest episode of GZERO World, whichstarts airing on public television nationwide beginning this Friday, February 5th. Check local listings.